Pharmacology · Opioid Pharmacology

Opioid Agonists: Classification, Pharmacokinetics, and Drug Profiles

Chemical families, metabolism, active metabolites, and high-yield drug distinctions

Opioid agonists fall into three chemical families — phenanthrenes (morphine, codeine, oxycodone, buprenorphine), phenylpiperidines (fentanyl, meperidine), and phenylheptylamines (methadone) — each with distinct metabolic pathways and clinical hazard profiles.
Codeine and tramadol are prodrugs requiring CYP2D6 conversion to active metabolites; poor metabolizers receive no analgesia while ultrarapid metabolizers face toxicity risk, with codeine now contraindicated in children under 12.
Active metabolites accumulate dangerously in renal failure: morphine-6-glucuronide (more potent than morphine itself) causes prolonged respiratory depression, and normeperidine (meperidine's metabolite) causes seizures.
Methadone's analgesic duration (4–8 hours) is far shorter than its half-life (24–36 hours), creating accumulation risk with repeated dosing; CYP3A4 interactions and QTc prolongation require ECG monitoring.
Meperidine combined with MAOIs produces a potentially fatal serotonergic or excitatory hyperthermic reaction — this combination is an absolute contraindication with no exceptions.

Abbreviations: CYP2D6 = cytochrome P450 2D6 · CYP3A4 = cytochrome P450 3A4 · M6G = morphine-6-glucuronide · MAOI = monoamine oxidase inhibitor · SSRI = selective serotonin reuptake inhibitor · QTc = corrected QT interval · ECG = electrocardiogram · NMDA = N-methyl-D-aspartate

Chemical Classification

Family 1

Phenanthrenes

Natural: morphine, codeine
Semisynthetic: oxycodone, hydrocodone, hydromorphone, buprenorphine
Also: naloxone, naltrexone
Largest opioid chemical family
Most reactions are histamine release, not true allergy

Family 2

Phenylpiperidines

Meperidine — neuroexcitatory metabolite normeperidine
Fentanyl family — highly lipophilic, rapid onset
Fentanyl ~100× more potent than morphine
Metabolized by CYP3A4

Family 3

Phenylheptylamines

Methadone — mu agonist + NMDA antagonist
Long, unpredictable half-life (24–36 hours)
QTc prolongation risk
Metabolized by CYP3A4

Pharmacokinetic Concepts

Concept	Mechanism	Clinical Implication
First-pass effect	Oral opioids metabolized in liver before reaching circulation	Oral dose must be higher than intravenous dose for same effect
Lipophilicity	High lipophilicity = rapid blood-brain barrier penetration	Fentanyl onset 1–2 min; morphine onset 15–20 min
Active metabolites	M6G (more potent than morphine); normeperidine (neuroexcitatory)	Accumulate in renal failure; M6G causes respiratory depression; normeperidine causes seizures
CYP2D6 polymorphism	Codeine and tramadol require conversion to active metabolite	Poor metabolizers: no analgesia; ultrarapid metabolizers: toxicity risk
Transdermal depot	Fentanyl patch builds subcutaneous reservoir over 12–24 hours	Effect persists 12–24 hours after patch removal; heat accelerates absorption

High-Yield Drug Profiles

Prototype

Morphine

Full mu agonist prototype
Active metabolite: M6G (more potent)
Accumulates in renal failure → prolonged respiratory depression
Histamine release with rapid intravenous injection

Prodrug

Codeine

Requires CYP2D6 conversion to morphine for analgesia
Poor metabolizers: no analgesia
Ultrarapid metabolizers: morphine toxicity
Contraindicated in children under 12 and breastfeeding mothers
Also used as antitussive at subanalgesic doses

High Potency

Fentanyl

~100× more potent than morphine
Rapid onset (1–2 min IV) due to high lipophilicity
Transdermal patch: 72-hour delivery; do not cut; avoid heat
CYP3A4 metabolism — drug interactions important
Illicit fentanyl driving overdose epidemic

Long-Acting

Methadone

Mu agonist + NMDA receptor antagonist
Half-life 24–36 hours (variable); analgesic duration only 4–8 hours
QTc prolongation → monitor ECG
CYP3A4 interactions (inducers/inhibitors alter levels)
Used for opioid use disorder and chronic pain

High-Yield Danger Pairs

Meperidine + MAOIs: serotonin syndrome or excitatory hyperthermic reaction — potentially fatal.

Tramadol + MAOIs or SSRIs: serotonin syndrome risk.

Morphine + renal failure: M6G accumulates → respiratory depression.

Meperidine + renal failure: normeperidine accumulates → seizures.

Methadone + CYP3A4 inhibitors: elevated methadone levels → QTc prolongation and respiratory depression.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapter 31: Opioid Analgesics and Antagonists	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 20: Opioids, Analgesia, and Pain Management	McGraw-Hill, 2023
Trescot AM, Datta S, Lee M, Hansen H	Opioid pharmacology	Pain Physician. 2008;11(2 Suppl):S133–S153
Chou R, Fanciullo GJ, Fine PG, et al	Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain	J Pain. 2009;10(2):113–130
Crews KR, Gaedigk A, Dunnenberger HM, et al	Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy	Clin Pharmacol Ther. 2012;91(2):321–326
Stamer UM, Stuber F	The pharmacogenetics of analgesia	Expert Opin Pharmacother. 2007;8(14):2235–2245
Kaplan R, Parris WC, Citron ML, et al	Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain	J Clin Oncol. 1998;16(10):3230–3237
Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC	QTc interval screening in methadone treatment	Ann Intern Med. 2009;150(6):387–395
Boyer EW	Management of opioid analgesic overdose	N Engl J Med. 2012;367(2):146–155
United States Food and Drug Administration	Drug safety communication: FDA restricts use of prescription codeine pain and cough medicines in children	FDA.gov. 2017